Please Wait.....
Report
Ventricular Assist Device - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)
Market Report I 2025-06-01 I 115 Pages I Mordor Intelligence
Ventricular Assist Device Market Analysis
The Ventricular Assist Devices market is valued at USD 1.73 billion in 2025 and is forecast to reach USD 2.61 billion by 2030, advancing at an 8.53% CAGR over the period. Demand grows as ageing populations swell the pool of advanced-heart-failure patients and technological progress raises the clinical ceiling for mechanical circulatory support. Device makers are moving beyond bridge-to-transplant use cases, widening the total addressable Ventricular Assist Devices market through permanent support indications and fully implantable designs. Real-world data from large registries such as INTERMACS is driving evidence-based refinements in patient selection, while reimbursement expansions in key regions strengthen provider confidence. Simultaneously, new magnetic-levitation pumps and wireless power platforms lower adverse-event rates, reinforcing their role as long-term cardiac replacements.
Global Ventricular Assist Device Market Trends and Insights
Growing burden of cardiac diseases & heart failure
Heart-failure prevalence rose to 6.7 million Americans in 2025 and will climb to 11.4 million by 2050, widening the patient base for mechanical support. Younger cohorts and racial minorities are showing steeper incidence curves, which shifts device demand toward patients likely to need decades of circulatory assistance. Estimates place the cumulative cost of heart failure at USD 420 billion by mid-century, encouraging payers to support durable devices over repeated hospitalizations.
Technological advances
Magnetic levitation pumps such as HeartMate 3 post 63.3% five-year survival and lower thrombosis risk than earlier bearings-based systems. Miniaturised percutaneous pumps now use 9 Fr delivery profiles with 100% valve-crossing success in more than 500 procedures. Early studies on wireless power transfer demonstrate safe energy delivery across seven meters, pointing to future cable-free, fully implantable platforms.
High device and procedure costs
Implantation averages USD 175,420 and total stay costs approach USD 193,192, with a further USD 52,068 for readmissions, frustrating adoption in cost-sensitive markets. Limited insurer coverage and large capital budgets deter smaller centres, even as cost-effectiveness improves with battery longevity and reduced complication rates.
Other drivers and restraints analyzed in the detailed report include:
Expanding destination therapy amid organ donor shortage / Ageing population and healthcare spending / Device-related complications and recalls /
For complete list of drivers and restraints, kindly check the Table Of Contents.
Segment Analysis
Left Ventricular Assist Devices command 73.24% of 2024 revenues, the largest slice of the Ventricular Assist Devices market. Their 9.24% CAGR to 2030 reflects broad clinical eligibility and strong data on long-term survival. The Ventricular Assist Devices market size for LVADs is forecast to expand steadily as magnetic levitation platforms reduce thrombosis and pump stoppage rates. LVAD innovation now centres on wireless power and miniature control units, features that will narrow the gap with total artificial hearts.
Right Ventricular Assist Devices fill niche needs in isolated right-side failure, and Biventricular systems address complex bi-ventricle dysfunction, while total artificial hearts such as Aeson progress in pilot roll-outs. Clinical evidence highlights a 14-year support record for a single LVAD recipient, underscoring the destination-therapy potential of new models.
Ventricular Assist Devices Market Report is Segments by Product Type (Left Ventricular Assist Device (LVAD), Right Ventricular Assist Device (RVAD) and More), Design (Implantable VAD, Transcutaneous/External VAD and More), Application/ Therapy (Bridge-To-Transplant (BTT), Destination Therapy, and More), and Geography (North America, Europe and More). The Market Forecasts are Provided in Terms of Value (USD).
Geography Analysis
North America holds 42.68% of 2024 sales, reflecting robust Medicare coverage, centre-of-excellence networks, and a rich innovation pipeline. Registry data and outcome transparency continue to boost clinician confidence. The region is the primary launch ground for new platforms granted FDA breakthrough designation, enhancing first-mover revenues.
Europe presents steady uptake, leveraging harmonised regulatory frameworks and established heart-failure networks. Adoption is tempered by slower reimbursement updates and occasional device lag, yet the region is home to landmark innovations like the Aeson total artificial heart and strong academic-industry partnerships.
Asia-Pacific is the fastest growing at a 10.56% CAGR. Urbanising economies and rising cardiovascular risk deepen unmet need, while policy reforms widen device reimbursement. However, limited trained personnel and cost constraints slow penetration in secondary cities, making training programmes and public-private financing critical.
List of Companies Covered in this Report:
Abbott Laboratories / Medtronic / Johnson and Johnson (Abiomed) / Berlin Heart / SynCardia Systems / Jarvik Heart / BiVACOR / Calon Cardio-Technology Ltd. / Carmat / ReliantHeart Inc. / Evaheart Inc. / Supira Medical / CardioBridge GmbH / Lepu Medical / CH Biomedical Inc. / Corwave / Windmill Cardiovascular Systems / VentureMed Group / Sun Medical Technology Research Corp. /
Additional Benefits:
The market estimate (ME) sheet in Excel format /
3 months of analyst support /
1 Introduction
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 Research Methodology
3 Executive Summary
4 Market Landscape
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Burden Of Cardiac Diseases & Heart Failure
4.2.2 Technological Advances
4.2.3 Expanding Destination-Therapy Amid Organ Donor Shortage
4.2.4 Rising Aging Population and Healthcare Spending
4.2.5 Increased Clinical Trials and New Device Approval
4.2.6 Rising Awareness and Adoption of Minimally Invasive and Percutaneous VADs
4.3 Market Restraints
4.3.1 High Device & Procedure Costs
4.3.2 Device-Related Complications Coupled with Product Recall
4.3.3 Availability of Alternatives and Evolving Heart Therapies
4.3.4 Shortage Of Trained LVAD Coordinators In Emerging Markets
4.4 Value / Supply-Chain Analysis
4.5 Regulatory Landscape
4.6 Technology Outlook
4.7 Porter's Five Forces Analysis
4.7.1 Bargaining Power of Suppliers
4.7.2 Bargaining Power of Buyers
4.7.3 Threat of New Entrants
4.7.4 Threat of Substitutes
4.7.5 Intensity of Competitive Rivalry
5 Market Size and Growth Forecasts (Value-USD)
5.1 By Product Type
5.1.1 Left Ventricular Assist Device (LVAD)
5.1.2 Right Ventricular Assist Device (RVAD)
5.1.3 Biventricular Assist Device (BIVAD)
5.1.4 Total Artificial Heart (TAH)
5.2 By Design
5.2.1 Implantable VAD
5.2.2 Transcutaneous / External VAD
5.2.3 Percutaneous Micro-axial VAD
5.3 By Application / Therapy
5.3.1 Bridge-to-Transplant (BTT)
5.3.2 Destination Therapy (DT)
5.3.3 Bridge-to-Recovery (BTR)
5.3.4 Bridge-to-Decision
5.4 By Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 Competitive Landscape
6.1 Market Concentration
6.2 Market Share Analysis
6.3 Company profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products and Services, and Recent Developments)
6.3.1 Abbott Laboratories
6.3.2 Medtronic plc
6.3.3 Johnson and Johnson (Abiomed)
6.3.4 Berlin Heart GmbH
6.3.5 SynCardia Systems LLC
6.3.6 Jarvik Heart Inc.
6.3.7 BiVACOR Inc.
6.3.8 Calon Cardio-Technology Ltd.
6.3.9 CARMAT
6.3.10 ReliantHeart Inc.
6.3.11 Evaheart Inc.
6.3.12 Supira Medical
6.3.13 CardioBridge GmbH
6.3.14 Lepu Medical Technology
6.3.15 CH Biomedical Inc.
6.3.16 Corwave
6.3.17 Windmill Cardiovascular Systems
6.3.18 VentureMed Group
6.3.19 Sun Medical Technology Research Corp.
7 Market Opportunities and Future Outlook
7.1 White-Space and Unmet-Need Assessment
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security